BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32296917)

  • 1. Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran.
    Bandalizadeh Z; Shokohi T; Moosazadeh M; Keikha N; Seyedpor H; Rabie Rudsari M; Babamahmoudi F; Ghasemian R; Mardani M; Javanian M; Soleimanpour S; Sefidgar AA; Shokri M; Gouya MM; Seyedmousavi S
    Curr Microbiol; 2020 Aug; 77(8):1667-1672. PubMed ID: 32296917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of cryptococcal antigenuria at initial HIV diagnosis in KwaZulu-Natal.
    Drain PK; Kleene JM; Coleman SM; Losina E; Katz JN; Giddy J; Ross D; Freedberg KA; Bassett IV
    HIV Med; 2015 Nov; 16(10):640-4. PubMed ID: 25958770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.
    McKenney J; Bauman S; Neary B; Detels R; French A; Margolick J; Doherty B; Klausner JD
    Clin Infect Dis; 2015 Mar; 60(6):959-65. PubMed ID: 25422390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Cryptococcus antigen in human immunodeficiency virus-positive Turkish patients by using the Dynamiker
    Karaman E; Ilkit M; Kuşçu F
    Mycoses; 2019 Oct; 62(10):961-968. PubMed ID: 31344286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil.
    Vidal JE; Toniolo C; Paulino A; Colombo A; Dos Anjos Martins M; da Silva Meira C; Pereira-Chioccola VL; Figueiredo-Mello C; Barros T; Duarte J; Fonseca F; Alves Cunha M; Mendes C; Ribero T; Dos Santos Lazera M; Rajasingham R; Boulware DR
    Trop Med Int Health; 2016 Dec; 21(12):1539-1544. PubMed ID: 27699970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated Prevalence of Cryptococcus Antigenemia (CrAg) among HIV-Infected Adults with Advanced Immunosuppression in Namibia Justifies Routine Screening and Preemptive Treatment.
    Sawadogo S; Makumbi B; Purfield A; Ndjavera C; Mutandi G; Maher A; Kaindjee-Tjituka F; Kaplan JE; Park BJ; Lowrance DW
    PLoS One; 2016; 11(10):e0161830. PubMed ID: 27760140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude of Cryptococcal Antigenemia among HIV Infected Patients at a Referral Hospital, Northwest Ethiopia.
    Derbie A; Ayalew W; Mekonnen D; Alemu M; Mulugeta Y
    Ethiop J Health Sci; 2018 Jul; 28(4):369-374. PubMed ID: 30607049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and outcomes of cryptococcal antigenemia in HIV-seropositive patients hospitalized for suspected tuberculosis in Uganda.
    Andama AO; den Boon S; Meya D; Cattamanchi A; Worodria W; Davis JL; Walter ND; Yoo SD; Kalema N; Haller B; Huang L;
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):189-94. PubMed ID: 23542636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of Cryptococcal antigenemia using a finger-prick lateral flow assay in individuals with advanced HIV disease in Santarém Municipality, Brazilian Amazon Basin.
    Assy JGPL; Said RDC; Pinheiro OC; Brandão ADS; Boulware DR; França FOS; Vidal JE
    Med Mycol; 2021 Sep; 59(9):909-915. PubMed ID: 33908611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Cryptococcal Antigen Testing in Immunosuppressed HIV-positive Children and Adolescents.
    Zuma P; Ramsamy Y; Mlisana K; Archary M
    Pediatr Infect Dis J; 2020 Mar; 39(3):217-220. PubMed ID: 31725553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcal antigenemia and associated risk factors among ART-naïve and ART-experienced HIV-infected peoples at selected health institutions of Mekelle, Northern Ethiopia.
    Hailu K; Niguse S; Hagos K; Abdulkader M
    Microbiologyopen; 2019 Jun; 8(6):e00746. PubMed ID: 30277315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis.
    Li Y; Huang X; Chen H; Qin Y; Hou J; Li A; Wu H; Yan X; Chen Y
    BMC Infect Dis; 2020 Jun; 20(1):410. PubMed ID: 32532212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence and factors associated with cryptococcal antigenemia in HIV-infected patients in Cotonou/Benin].
    Ogouyèmi-Hounto A; Zannou DM; Ayihounton G; Ahouada C; Azon-Kouanou A; Acakpo J; Sissinto Savi de Tove Y; Kinde Gazard D
    J Mycol Med; 2016 Dec; 26(4):391-397. PubMed ID: 27641486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, Tanzania.
    Magambo KA; Kalluvya SE; Kapoor SW; Seni J; Chofle AA; Fitzgerald DW; Downs JA
    J Int AIDS Soc; 2014; 17(1):19040. PubMed ID: 25109284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Advanced HIV Disease, Cryptococcal Antigenemia, and Suboptimal Clinical Outcomes Among Those Enrolled in Care in Vietnam.
    Dat VQ; Lyss S; Dung NTH; Hung LM; Pals SL; Anh HTV; Kinh NV; Bateganya M
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):487-496. PubMed ID: 34446679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.
    Ford N; Shubber Z; Jarvis JN; Chiller T; Greene G; Migone C; Vitoria M; Doherty M; Meintjes G
    Clin Infect Dis; 2018 Mar; 66(suppl_2):S152-S159. PubMed ID: 29514236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.